Image

North America Ovarian Cancer Diagnostics Market – Industry Trends and Forecast to 2030

Medical Devices

Image

North America Ovarian Cancer Diagnostics Market – Industry Trends and Forecast to 2030

  • Medical Devices
  • Published Report
  • Nov 2022
  • North America
  • 350 Pages
  • No of Tables: 35
  • No of Figures: 35

North America Ovarian Cancer Diagnostics Market – Industry Trends and Forecast to 2030

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period 2022–2030
Diagram Market Size (Base Year) USD 3,124.06 USD Billion
Diagram Market Size (Forecast Year) USD 5,675.36 USD Billion
Diagram CAGR %

Major Markets Players

  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

North America Ovarian Cancer Diagnostics Market, By Product Type (Instruments, Kits and Reagents), Procedure Type (Biopsy Test, Medical Imaging Test, Blood Markers Testing and Genetic Testing), Cancer Type (Germ Cell, Epithelial Tumor and Stromal Cell Tumor), End User (Cancer Diagnostic Centers, Hospital Laboratories, Research Institutes and Others) - Industry Trends and Forecast to 2030.

Ovarian Cancer Diagnostics Market

North America Ovarian Cancer Diagnostics Market Analysis and Insights

Ovarian cancer is the type of cancer that forms in tissues of the ovary (one of a pair of female reproductive glands in which the ova, or eggs, are formed). Most ovarian cancers are either ovarian epithelial cancers (cancer that begins in the cells on the surface of the ovary) or malignant germ cell tumors (cancer that begins in egg cells). The tests and procedures used to diagnose ovarian cancer includes the pelvic exam, imaging tests, blood tests, surgery and among others. During a pelvic exam, the doctor inserts gloved fingers into the vagina and simultaneously presses a hand on the abdomen in order to feel (palpate) the pelvic organs.

Ovarian Cancer Diagnostics Market

Ovarian Cancer Diagnostics Market

North America ovarian cancer diagnostics market is expected to grow in the forecast period of 2023 to 2030. Data Bridge Market Research analyses that the market is growing with a CAGR of 7.8% in the forecast period of 2023 to 2030 and is expected to reach USD 5,675.36 million by 2030 from USD 3,124.06 million in 2022.

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customisable to 2020-2016)

Quantitative Units

Revenue in USD Million

Segments Covered

By Product Type (Instruments, Kits and Reagents), Procedure Type (Biopsy Test, Medical Imaging Test, Blood Markers Testing and Genetic Testing), Cancer Type (Germ Cell, Epithelial Tumor and Stromal Cell Tumor), End User (Cancer Diagnostic Centers, Hospital Laboratories, Research Institutes and Others)

Countries Covered

U.S., Canada and Mexico

Market Players Covered

F. Hoffmann-La Roche Ltd, Tosoh India Pvt. Ltd., Luminex Corporation, Quest Diagnostics Incorporated, Thermo Fisher Scientific Inc., Ngenebio, Abbott, Siemens healthcare private limited, Myriad genetics Inc., Bio-rad laboratories, Inc., R&d systems, Inc., Foundation medicine, Inc., Biosupply ltd, Lcm genect srl, Inex innovate private limited, Abcam plc., Monobind Inc., Fujirebio, Mp biomedicals, Biovision Inc., Boster biological technology, Biogenix Inc. Pvt. Ltd., Genway biotech and Lifespan biosciences, Inc.

Market Definition of North America Ovarian Cancer Diagnostics Market

Ovarian cancer is most common in women between the ages of 50 and 79. It is becoming more prevalent as the world's geriatric population grows and there is a greater emphasis on early detection and treatment, which is expected to accelerate ovarian cancer diagnostic market development. Increasing government investment in raising awareness about early cancer detection as well as increasing health-care spending would also propel business growth. Obesity appears to play a significant role in the development of ovarian cancer. Other lifestyle choices that can raise the risk include smoking, drinking, and not having children. Since ovarian cancer is not easily detectable, women who are at risk of developing the disease must undergo routine testing to identify the disease early, allowing the market to expand.

The North America ovarian cancer diagnostic market is growing in the forecast year due to the rise in market players and the availability of advanced services. Along with this, manufacturers are engaged in R&D activity for launching novel services in the market. The increasing research in ovarian cancer diagnostics and development is further boosting the market growth. However, difficulties in ovarian cancer screening techniques might hamper the growth of the North America ovarian cancer diagnostic market in the forecast period.

North America Ovarian Cancer Diagnostics Market Dynamics

Drivers

  • Growing Ovarian Cancer Awareness

Growing ovarian cancer awareness has led to an increased demand for timely cancer detection, leading to market growth.

Ovarian cancer is one of the major causes of rising mortality rates among female populations worldwide, which is fuelling market growth over the next five years. Cancer in the ovaries and cysts is becoming more common due to various factors such as environmental factors and genetic mutations.

Ovarian cancer is a type of cancer that affects women’s egg-producing organs, the ovaries. Ovarian cancer is difficult to diagnose because the symptoms are vague and are often detected only after cancer has spread through the stomach and pelvis, making it difficult to cure.

As a result, improved diagnostic processes and techniques are required to determine the cancer stage to treat. Furthermore, the rising mortality rate from ovarian cancer is concerning, emphasizing the importance of early detection so that treatment can be provided.

Due to an increase in awareness about ovarian cancer, it is expected to act as a driving factor for market growth.

  • Improved Diagnostic Processes and Techniques

Screening tests and exams are used to detect a disease, such as cancer, in people who do not have any symptoms. There has been a lot of research to develop a screening test for ovarian cancer, but there has not been much success so far. The two tests used most often (in addition to a complete pelvic exam) to screen for ovarian cancer are Transvaginal Ultrasound (TVUS) and the CA-125 blood test.

TVUS is a test that uses sound waves to look at the uterus, fallopian tubes, and ovaries by putting an ultrasound wand into the vagina. It can help find a mass (tumor) in the ovary, but it cannot actually tell if a mass is cancer or benign. When it is used for screening, most of the masses found are not cancer.

The CA-125 blood test measures the amount of a protein called CA-125 in the blood. Many women with ovarian cancer have high levels of CA-125. This test can be useful as a tumor marker to help guide treatment in women known to have ovarian cancer because a high level often goes down if treatment is working. But checking CA-125 levels is not as useful as a screening test for ovarian cancer.

Thus, due to the increase in improved diagnostic processes and techniques, it is expected to act as a driving factor for market growth.

RESTRAINTS

High Cost of Diagnosis

Worldwide, the costs of cancer treatment have increased. Health industries are facing several challenges like medical costs for cancer care. The cost of cancer care in 2010 was USD 124.60 billion which was projected to increase to USD 173.00 billion by 2020 with cancer drug prices and acute hospital care as the main drivers. Hence, the increased cost of diagnostic agents production is hampering the market growth.

Lack of Skilled Professionals

Healthcare professionals involved in the diagnostic process have an obligation and ethical responsibility to employ clinical reasoning skills, evaluate, and manage a patient's medical problems. When a diagnosis is accurate and made in a timely manner, a patient has the best opportunity for a positive health outcome because clinical decision-making will be tailored to a correct understanding of the patient's health problem. The lack of skilled professionals may hinder the recovery process of the patient and thus, may hamper the market growth.

OPPORTUNITIES

Increasing Healthcare Expenditure for Cancer Diagnosis and Treatment

Across the globe, R&D activities are escalating owing to public health expenditure with economic performances whereas, the healthcare industry ranks second among all industries when it comes to the amount spent on healthcare. Rising healthcare expenditure can result in better provision of R&D opportunities. It is anticipated to upsurge the demand for ovarian cancer diagnostics.

Increasing healthcare expenditure for cancer treatment also helps patients to take hassle-free advanced diagnostics and treatment for fast recovery. The spending on healthcare is made up of the combination of out-of-pocket payments (people paying for their own care), government expenditure, and sources including health insurance and activities by Non-Governmental Organizations (NGOs). Due to this increasing healthcare expenditure for cancer treatment, it acts as an opportunity for market growth.

CHALLENGES

Strict Regulations and Standards for the Approval and Commercialization of Cancer Diagnostic Products

The stringent regulations for commercialization of any product in the market are proving to be a big challenge for manufacturers of cancer diagnostic products in the U.S. and European region. Every country has its own regulations and has a different body for regulatory procedures.

In the U.S., manufacturers require marketing authorization approval for IVD products for human use. The product must be labeled in accordance with labeling regulations. Establishments involved in the production and distribution of medical devices intended for commercial distribution in the U.S. are required to register with the FDA. Registration provides the FDA with the location of medical device manufacturing facilities and importers. Registration of an establishment is not an approval of the establishment or its devices by the FDA, that is, it does not provide FDA authorization to market the device. Unless exempted, premarketing authorization is required before a device can be placed into commercial distribution in the U.S.

The regulatory requirement for approvals of marketing as well as the declaration of conformity and the time required for regulatory review may vary for different products. The company which fails to get regulatory approval harms the business because without getting approval on the products, manufacturers are not able to launch their product in the market and for this reason, strict regulations and standards for the approval and commercialization of cancer diagnostic products act as a restraining factor for market growth.

Recent Developments

  • In November 2022, Myriad genetics Inc. announced that it has acquired Gateway Genomics, LLC, The acquisition strengthens Myriad Genetics’ portfolio of Women’s Health products, expanding access to personalized genetic tests during the reproductive stage of a women’s life and beyond. With SneakPeek, Myriad now serves women earlier in their pregnancy, providing data-driven genetic insights through their lifetime with the Prequel non-invasive prenatal screen, Foresight carrier screen, and MyRisk Hereditary Cancer Test with Risk Score for all ancestries, this will help the company to increase their revenue.
  • In October 2022, Quest Diagnostics announced the new phase of collaboration with Decode health, in the starting phase of collaboration, the two parties developed RNA (transcriptome) sequencing capabilities based on both parties' next-generation sequencing, analytics and clinical expertise. The collaboration is significant as biomarker-based data can help reduce the time and cost of developing novel diagnostic tests and identifying new drug targets for different types of cancers (breast, prostate and ovarian cancer). This collaboration helps the company to find innovative paths in the field of R&D and increases the North America presence of the company.

North America Ovarian Cancer Diagnostics Market Scope

North America ovarian cancer diagnostics market is segmented into product type, procedure type, cancer type and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Product Type

  • Instruments
  • Kits and Reagents

On the basis of product type, the North America ovarian cancer diagnostics market is segmented into instruments and kits and reagents.

Procedure Type

  • Blood Markers Testing
  • Medical Imaging Test
  • Biopsy Tests
  • Genetic Testing

On the basis of procedure type, the North America ovarian cancer diagnostics market is segmented into blood markers testing, medical imaging test, biopsy tests and genetic testing

Cancer Type

  • Epithelial Tumor
  • Germ Cell
  • Stromal Cell Tumor

On the basis of cancer type, the North America ovarian cancer diagnostics market is segmented into epithelial tumor, germ cell and stromal cell tumor

End User

On the basis of end user, the North America ovarian cancer diagnostics market is segmented into cancer diagnostic centers, hospital laboratories, research institutes and others

North America Ovarian Cancer Diagnostics Market Regional Analysis/Insights        

The North America ovarian cancer diagnostics market is analyzed, and market size insights and trends are provided by country, product type, procedure type, cancer type and end user, as referenced above.

The countries covered in this market report U.S., Canada and Mexico.

U.S. is dominating the North America ovarian cancer diagnostics market in terms of market share and revenue and will continue to flourish its dominance during the forecast period. This is due to the high prevalence and incidence of neurological disorders in the region, and growing R&D investments and the launch of new products are boosting the market

The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of North American brands and their challenges faced due to competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and North America Ovarian Cancer Diagnostics Market Share Analysis

The ovarian cancer diagnostics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, North America presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Ovarian Cancer Diagnostics Market.

Some of the major players operating in the North America ovarian cancer diagnostics market are F. Hoffmann-la roche ltd, Tosoh india pvt. Ltd., Luminex corporation, Quest diagnostics incorporated, Thermo fisher scientific Inc., Ngenebio, Abbott, Siemens healthcare private limited, Myriad genetics Inc., Bio-rad laboratories, Inc., R&d systems, Inc., Foundation medicine, Inc., Abcam plc., Monobind Inc., Mp biomedicals, Biovision Inc., Boster biological technology, Biogenix Inc. Pvt. Ltd., Genway biotech and Lifespan biosciences, Inc among others.


SKU-

TABLE 1 24-MONTH EPISODE-OF-CARE COSTS FOR EARLY-STAGE AND LATE-STAGE CANCERS BY PAYER (USD BILLION)

TABLE 2 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 3 NORTH AMERICA INSTRUMENTS IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 4 NORTH AMERICA KITS AND REAGENTS IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 5 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)

TABLE 6 NORTH AMERICA BLOOD MARKERS TESTING IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 7 NORTH AMERICA MEDICAL IMAGING TEST IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 8 NORTH AMERICA BIOPSY TEST IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 9 NORTH AMERICA GENETIC TESTING IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 10 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 11 NORTH AMERICA EPITHELIAL TUMOR IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 12 NORTH AMERICA GERM CELL IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 13 NORTH AMERICA STROMAL CELL TUMOR IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 14 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 15 NORTH AMERICA CANCER DIAGNOSTIC CENTERS IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 16 NORTH AMERICA HOSPITAL LABORATORIES IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 17 NORTH AMERICA RESEARCH INSTITUTES IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 18 NORTH AMERICA OTHERS IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 19 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 20 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 21 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)

TABLE 22 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 23 NORTH AMERICA OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 24 U.S. OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 25 U.S. OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)

TABLE 26 U.S. OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 27 U.S. OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 28 CANADA OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 29 CANADA OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)

TABLE 30 CANADA OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 31 CANADA OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 32 MEXICO OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 33 MEXICO OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION)

TABLE 34 MEXICO OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 35 MEXICO OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

FREQUENTLY ASK QUESTIONS

The North America Ovarian Cancer Diagnostics Market is projected to grow at a CAGR of 7.8% during the forecast period by 2030.
The future market value of the North America Ovarian Cancer Diagnostics Market is expected to reach USD 5,675.36 million by 2030.
The major players in the North America Ovarian Cancer Diagnostics Market are F. Hoffmann-La Roche Ltd, Tosoh India Pvt. Ltd., Luminex Corporation, Quest Diagnostics Incorporated, Thermo Fisher Scientific Inc., Ngenebio, Abbott, Siemens healthcare private limited, Myriad genetics Inc., Bio-rad laboratories, Inc., etc.
The countries covered in the North America Ovarian Cancer Diagnostics Market are U.S., Canada and Mexico.
Free Sample Report

CHOOSE LICENCE TYPE

  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials